GIDS Research Radar · Randomised controlled trial https://globalinfectiousdisease.com/research/ Published infectious-disease literature filtered to Randomised controlled trial. en Wed, 09 Sep 2026 07:02:01 GMT Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study. https://globalinfectiousdisease.com/research/articles/10-1080-21645515-2026-2716508-f8e301e4/ https://globalinfectiousdisease.com/research/articles/10-1080-21645515-2026-2716508-f8e301e4/ Tue, 25 Aug 2026 00:00:00 GMT Establishing the safety of this vaccine when combined with routine pediatric immunizations aids regulatory approval and clinical administration guidelines. The data contributes to understanding potential interactions within standard infant vaccination protocols. Diphtheria Tetanus Pertussis Meningococcal disease Varicella Hepatitis B Vaccination Treatment Randomised controlled trial Field evaluation of SumiLarv™ 2MR larvicide for controlling the invasive malaria vector Anopheles stephensi in Ethiopia: a randomised controlled trial https://globalinfectiousdisease.com/research/articles/10-1186-s12936-026-06089-3-b8294aa6/ https://globalinfectiousdisease.com/research/articles/10-1186-s12936-026-06089-3-b8294aa6/ Mon, 17 Aug 2026 00:00:00 GMT The findings suggest SumiLarv 2MR may be a suitable larval source management tool against the invasive urban-tolerant vector An. stephensi, which complicates existing malaria control in Ethiopia. Malaria Surveillance Treatment Climate and environment Randomised controlled trial Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial https://globalinfectiousdisease.com/research/articles/10-1016-j-jinf-2026-106784-7587e5cb/ https://globalinfectiousdisease.com/research/articles/10-1016-j-jinf-2026-106784-7587e5cb/ Sat, 01 Aug 2026 00:00:00 GMT The documented compatibility indicates potential administrative advantages for coordinating seasonal and shingles immunisations within standard adult care pathways. COVID-19 Influenza Zoster SARS Vaccination Treatment Randomised controlled trial Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101344-b6e9fecd/ https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101344-b6e9fecd/ Sat, 01 Aug 2026 00:00:00 GMT The data substantiate the sustained implementation of artemether-lumefantrine paired with primaquine while positioning the alternative pyronaridine-artesunate regimen as a reliable secondary option for areas confronting evolving drug resistance and diagnostic reliability concerns. Malaria Treatment Surveillance Diagnostics Randomised controlled trial Effects of attenuated influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2026-101422-edc10908/ https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2026-101422-edc10908/ Sat, 01 Aug 2026 00:00:00 GMT The findings suggest LAIV-induced increases in pneumococcal density in vaccinated toddlers may transiently raise pneumococcal acquisition risk among household members, which has implications for transmission modelling at individual and population scales. Influenza Vaccination Transmission dynamics Randomised controlled trial Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128863-a285187d/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128863-a285187d/ Sat, 01 Aug 2026 00:00:00 GMT Waning immunity following acellular pertussis vaccination has been observed in pertussis outbreaks, creating a need for more effective acellular pertussis vaccines. The findings support the potential use of this 2-component vaccine as a pertussis booster in adults. Pertussis Diphtheria Tetanus Vaccination Vaccine effectiveness Randomised controlled trial Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128870-0aa7ff23/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128870-0aa7ff23/ Sat, 01 Aug 2026 00:00:00 GMT The work explores alternative delivery methods intended to strengthen localized immune defenses against respiratory pathogens, highlighting areas for future clinical development. SARS COVID-19 Vaccination Treatment Randomised controlled trial Effectiveness and acceptability of an opt-out nudge to promote influenza vaccination among medical residents: A randomized controlled trial https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128894-87d1027b/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128894-87d1027b/ Sat, 01 Aug 2026 00:00:00 GMT Integrating behavioral prompts into routine clinical workflows may offer a supplementary mechanism for enhancing seasonal immunization coverage within academic medical centers. Influenza Vaccination Randomised controlled trial Timing of maternal Tdap vaccination: A dynamic balance between antibody induction and placental transfer efficiency https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128953-24484f5e/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128953-24484f5e/ Sat, 01 Aug 2026 00:00:00 GMT The results validate existing protocols recommending immunization within the specified mid-pregnancy timeframe while demonstrating operational flexibility for clinical scheduling. Pertussis Diphtheria Tetanus Vaccination Randomised controlled trial The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128970-71fefd82/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2026-128970-71fefd82/ Sat, 01 Aug 2026 00:00:00 GMT The findings demonstrate that multiple licensed COVID-19 booster vaccines remain effective at eliciting immune responses when given as fifth or subsequent doses, with acceptable safety profiles. The waning of responses by one year supports periodic booster recommendations for sustained protection. COVID-19 SARS Vaccination Treatment Randomised controlled trial Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00062-9-581e6928/ https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00062-9-581e6928/ Sat, 01 Aug 2026 00:00:00 GMT Findings address whether enhanced antigen dose or non-egg production platforms can improve immunogenicity against A(H3N2) strains, which have been associated with reduced effectiveness of egg-derived vaccines. Influenza Vaccination Treatment Randomised controlled trial Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01E vaccination: an observational ancillary immunological study of a phase 3 clinical trial https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00081-2-4c45715c/ https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-26-00081-2-4c45715c/ Sat, 01 Aug 2026 00:00:00 GMT The findings could inform immunological evaluation of RTS,S/AS01E by identifying antibody durability and maintenance, rather than peak responses alone, as potentially relevant correlates of vaccine efficacy. Malaria Vaccination Treatment Vaccine effectiveness Randomised controlled trial Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial https://globalinfectiousdisease.com/research/articles/10-1186-s12879-026-13741-5-f049bb89/ https://globalinfectiousdisease.com/research/articles/10-1186-s12879-026-13741-5-f049bb89/ Thu, 11 Jun 2026 00:00:00 GMT The findings provide treatment-duration evidence from Malaysian adults with chronic hepatitis C and may inform further evaluation of shorter ravidasvir/sofosbuvir regimens. The abstract does not establish programmatic recommendations, population-level effectiveness, or effects on transmission or mortality. Hepatitis C Hepatitis E Chronic hepatitis C Treatment Randomised controlled trial Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial https://globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1004877-2633a3dc/ https://globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1004877-2633a3dc/ Thu, 14 May 2026 00:00:00 GMT Mapping these precise humoral targets may assist researchers in designing future immunizations with enhanced longevity and defensive capability. Malaria Treatment Vaccination Randomised controlled trial Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2516491-76f08689/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2516491-76f08689/ Thu, 07 May 2026 00:00:00 GMT This work evaluates an alternative antigen presentation technology aimed at addressing ongoing respiratory disease burdens in aging populations. Successful validation of this platform could inform future immunization strategies targeting groups with historically reduced vaccine responsiveness. Influenza Vaccination Vaccine effectiveness Treatment Randomised controlled trial Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-26-00258-8-ecbd943f/ https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-26-00258-8-ecbd943f/ Wed, 01 Apr 2026 00:00:00 GMT These outcomes indicate that targeted immunoprophylaxis may serve as a supplementary preventive measure for youth in endemic zones, though current dosing regimens require optimization for maximum impact. Malaria Treatment Transmission dynamics Randomised controlled trial Artesunate–pyronaridine–atovaquone–proguanil and artesunate–fosmidomycin–clindamycin compared with standard artesunate–pyronaridine for the treatment of uncomplicated malaria (MultiMal): a randomised, controlled, clinical, phase 2 trial in Gabon and Ghana https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101245-4f0f82f3/ https://globalinfectiousdisease.com/research/articles/10-1016-j-lanmic-2025-101245-4f0f82f3/ Sun, 01 Mar 2026 00:00:00 GMT The authors position APAP and AFC as candidate multidrug combinations intended to address emerging artemisinin-reduced susceptibility in sub-Saharan Africa, warranting further clinical development. Malaria Treatment Antimicrobial resistance Randomised controlled trial Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-24-00143-9-c153178e/ https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-24-00143-9-c153178e/ Thu, 01 Aug 2024 00:00:00 GMT The paper provides context for tuberculosis vaccine development by describing a controlled human infection model intended for future evaluation of vaccine efficacy and potential correlates of protection. It does not provide evidence about population-level tuberculosis surveillance or current disease activity. Tuberculosis Vaccination Treatment Vaccine effectiveness Randomised controlled trial Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine https://globalinfectiousdisease.com/research/articles/10-1038-s41541-023-00630-0-71b194cd/ https://globalinfectiousdisease.com/research/articles/10-1038-s41541-023-00630-0-71b194cd/ Sat, 11 Mar 2023 00:00:00 GMT Establishing quantitative immunological benchmarks may assist regulatory agencies in evaluating vaccine performance during approval pathways. COVID-19 SARS Vaccination Outbreak investigation Vaccine effectiveness Randomised controlled trial Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults https://globalinfectiousdisease.com/research/articles/10-1038-s41467-023-36789-2-dee4d8b1/ https://globalinfectiousdisease.com/research/articles/10-1038-s41467-023-36789-2-dee4d8b1/ Mon, 06 Mar 2023 00:00:00 GMT A thermostable tuberculosis vaccine candidate that does not require refrigerated storage could improve vaccine access and deployment in resource-limited settings where cold-chain infrastructure is inadequate. Tuberculosis Vaccination Treatment Climate and environment Randomised controlled trial Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2200674-3e7524b3/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa2200674-3e7524b3/ Thu, 19 May 2022 00:00:00 GMT The trial provides randomized evidence that a third BNT162b2 dose given roughly 10–11 months after the primary series had an acceptable short-term safety profile and substantially reduced Covid-19 incidence relative to two doses during a median 2.5-month follow-up, informing booster-dose decision-making. SARS COVID-19 Vaccination Treatment Vaccine effectiveness Vaccine safety Randomised controlled trial Efficacy and safety of a quadrivalent influenza vaccine in children aged 6–35 months: A global, multiseasonal, controlled, randomized Phase III study https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-02-088-d70a105b/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2022-02-088-d70a105b/ Fri, 01 Apr 2022 00:00:00 GMT Children under 3 years represent an important target group for influenza vaccination, yet few prospective efficacy studies exist for this age group. This trial demonstrates that primary vaccination with quadrivalent influenza vaccine is well tolerated and effective in protecting young children against influenza. Influenza Vaccination Treatment Vaccine effectiveness Randomised controlled trial Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-21-00234-8-5b95152a/ https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-21-00234-8-5b95152a/ Mon, 01 Feb 2021 00:00:00 GMT This interim analysis provides evidence from a large-scale phase 3 trial supporting the efficacy and tolerability of a two-dose adenovirus-vectored COVID-19 vaccine in adults. COVID-19 SARS Vaccination Treatment Outbreak investigation Vaccine effectiveness Randomised controlled trial Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciaa1673-685f419f/ https://globalinfectiousdisease.com/research/articles/10-1093-cid-ciaa1673-685f419f/ Wed, 04 Nov 2020 00:00:00 GMT The paper is relevant to influenza vaccine development, especially efforts to improve breadth of immune responses against homologous and drifted strains in older adults. It may be useful for literature review on vaccine immunogenicity and tolerability, but it does not establish real-world effectiveness. Influenza Vaccination Vaccine effectiveness Treatment Randomised controlled trial Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0007955-be2809f8/ https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0007955-be2809f8/ Thu, 26 Dec 2019 00:00:00 GMT The findings are relevant to first-line therapy of uncomplicated enteric fever in the context of emerging antimicrobial resistance, and motivate further work on azithromycin dosing regimens and combination strategies. Typhoid fever Paratyphoid fever Treatment Vaccination Antimicrobial resistance Randomised controlled trial Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1903869-079acbe8/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1903869-079acbe8/ Thu, 21 Nov 2019 00:00:00 GMT Dengue was designated a WHO top 10 global health threat in 2019. This vaccine showed high efficacy against symptomatic and severe dengue in endemic settings, supporting its potential as a public health intervention for disease-endemic countries. Dengue Treatment Vaccination Vaccine effectiveness Randomised controlled trial Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-17-30313-4-26a9403a/ https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-17-30313-4-26a9403a/ Tue, 01 Aug 2017 00:00:00 GMT Findings informed dose selection for subsequent phase 3 evaluation of the rVSV∆G-ZEBOV-GP candidate, contributing evidence toward a deployable Ebola virus vaccine following the 2014 Zaire Ebola virus outbreak. Ebola Hemorrhagic Fever Vaccination Treatment Surveillance Outbreak investigation Randomised controlled trial Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2016-11-042-069215bc/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2016-11-042-069215bc/ Sun, 01 Jan 2017 00:00:00 GMT The paper is relevant to malaria vaccine policy because it supports country adoption discussions by summarizing projected burden reduction and cost-effectiveness under specified assumptions. It also notes that feasibility, scaling, and delivery constraints matter for implementation. Malaria Vaccination Transmission dynamics Vaccine effectiveness Randomised controlled trial Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-15-00486-7-1b1ae76c/ https://globalinfectiousdisease.com/research/articles/10-1016-s1473-3099-15-00486-7-1b1ae76c/ Tue, 01 Mar 2016 00:00:00 GMT The paper is relevant to Ebola vaccine development because it provides early human safety and immune-response data for a candidate vaccine during an outbreak context. It is positioned as evidence to support later-phase efficacy studies rather than as a population-level effectiveness assessment. Ebola Hemorrhagic Fever Treatment Vaccination Outbreak investigation Randomised controlled trial Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-15-00725-4-30b7693f/ https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-15-00725-4-30b7693f/ Fri, 01 Jan 2016 00:00:00 GMT The models predict significant public health impact and high cost-effectiveness of RTS,S/AS01 vaccination across a wide range of malaria transmission settings in Africa, though implementation decisions would need to consider local burden levels, existing intervention coverage and cost-effectiveness, health priorities, financing, and delivery system capacity. Malaria Plasmodium falciparum malaria Vaccination Vaccine effectiveness Transmission dynamics Health policy Randomised controlled trial Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-15-60553-0-d75ff618/ https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-15-60553-0-d75ff618/ Mon, 01 Jun 2015 00:00:00 GMT This is an early clinical evaluation of an Ebola vaccine candidate, so it is relevant to vaccine development and preparedness work. The study addresses a vaccine targeting the 2014 epidemic strain rather than providing outbreak surveillance evidence. Ebola Vaccination Outbreak investigation Treatment Randomised controlled trial Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-14-62385-0-38ad575b/ https://globalinfectiousdisease.com/research/articles/10-1016-s0140-6736-14-62385-0-38ad575b/ Wed, 01 Apr 2015 00:00:00 GMT The paper is relevant to vaccine development for two high-fatality viral diseases and to early clinical evaluation of candidate vaccines in an African setting. It also provides context for later development work on Ebola vaccine antigens. Ebola Treatment Vaccination Outbreak investigation Randomised controlled trial Efficacy, Safety, and Immunogenicity of an Enterovirus 71 Vaccine in China https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1304923-4731dbbd/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1304923-4731dbbd/ Thu, 27 Feb 2014 00:00:00 GMT The trial addresses EV71, identified in the abstract as a major cause of outbreaks of hand, foot, and mouth disease and herpangina, in a large pediatric population in China. Herpangina Treatment Vaccination Surveillance Vaccine effectiveness Randomised controlled trial Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2013-07-007-2ac0727c/ https://globalinfectiousdisease.com/research/articles/10-1016-j-vaccine-2013-07-007-2ac0727c/ Sun, 01 Sep 2013 00:00:00 GMT The findings demonstrate that a single dose of either adjuvanted or non-adjuvanted A(H1N1)pdm09 vaccine can induce protective antibody levels that persist through six months in adults aged 18-64 years, informing pandemic vaccination strategies. The adjuvanted formulation achieved comparable immunogenicity with a lower antigen dose, which may support vaccine supply during pandemic responses. Influenza Vaccination Treatment Vaccine effectiveness Randomised controlled trial First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1102287-824fb250/ https://globalinfectiousdisease.com/research/articles/10-1056-nejmoa1102287-824fb250/ Thu, 17 Nov 2011 00:00:00 GMT A phase 3 malaria vaccine milestone that helps connect current malaria surveillance with prevention evidence. Malaria Vaccination Vaccine effectiveness Treatment Randomised controlled trial A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0001267-63e33f35/ https://globalinfectiousdisease.com/research/articles/10-1371-journal-pntd-0001267-63e33f35/ Tue, 02 Aug 2011 00:00:00 GMT Dengue has emerged as the most important arboviral infection globally. The safety and immunogenicity profile observed supports the inclusion of rDEN1Δ30 in a tetravalent dengue vaccine under Phase I evaluation. Dengue Malaria Vaccination Treatment Vaccine effectiveness Randomised controlled trial Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Mali: A Randomised, Double-Blind, Placebo-Controlled Trial https://globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1000407-089aa9d7/ https://globalinfectiousdisease.com/research/articles/10-1371-journal-pmed-1000407-089aa9d7/ Tue, 01 Feb 2011 00:00:00 GMT The paper frames the intervention as a potential addition to malaria control in seasonal transmission areas, including settings with high insecticide-treated net use. Its context is prevention in young children rather than treatment of established illness. Malaria Treatment Surveillance Transmission dynamics Randomised controlled trial Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial https://globalinfectiousdisease.com/research/articles/10-1136-bmj-39010-581354-55-48423e96/ https://globalinfectiousdisease.com/research/articles/10-1136-bmj-39010-581354-55-48423e96/ Fri, 01 Dec 2006 00:00:00 GMT The findings suggest that staff influenza vaccination programs in care homes may reduce mortality and healthcare utilization among vulnerable residents during periods of moderate influenza activity. Influenza Vaccination Transmission dynamics Treatment Health policy Randomised controlled trial Effective control of dengue vectors with curtains and water container covers treated with insecticide in Mexico and Venezuela: cluster randomised trials https://globalinfectiousdisease.com/research/articles/10-1136-bmj-332-7552-1247-611e8f2b/ https://globalinfectiousdisease.com/research/articles/10-1136-bmj-332-7552-1247-611e8f2b/ Thu, 25 May 2006 00:00:00 GMT Insecticide-treated curtains and water container covers reduced dengue vector densities to low levels across entire study communities, suggesting potential for area-wide dengue transmission reduction through this intervention approach. Dengue Climate and environment Transmission dynamics Treatment Randomised controlled trial